Background
Osteoporosis and fragility fractures affect a large proportion of the population and have significant health and economic consequences. This thesis addresses several emerging questions regarding bone metabolism and the entity of osteoporosis, specifically:
- How is bone mineral homeostasis related to energy metabolism and cardiovascular health?
- By what mechanisms do certain disease states and medications contribute to the development of secondary osteoporosis?
- Why do different tools used to estimate fracture risk sometimes give discordant results for the same patient, and how should these be addressed in clinical practice?
- How can we better understand the side effect profiles of osteoporosis treatments, and develop strategies to mitigate adverse effects?
Methods
Six studies are described herein:
- An analysis of relationships between circulating parathyroid hormone (PTH), cardiometabolic risk factors, and bone mineral density (BMD) in healthy men
- An assessment of associations between phosphate and adiposity in three cohorts, and between fibroblast growth factor 23 (FGF23) and weight in a fourth cohort
- A meta-analysis of randomized controlled trials (RCTs) assessing the effects of thiazolidinedione (TZD) medications on BMD and bone turnover
- 4An assessment of the effects of patient characteristics on absolute fracture risk estimates generated by the FRAX and Garvan fracture risk calculators
- A crossover RCT evaluating the acute effects of calcium supplementation on blood pressure in postmenopausal women
- A RCT assessing the effect of oral dexamethasone on prevention of the acute phase response (APR) following administration of zoledronic acid
Results & Conclusions
Results and their implications are summarized as follows:
- PTH was positively associated with markers of cardiometabolic risk, including measures of adiposity and coronary artery calcification, but not with BMD. Adiposity may represent a cause of secondary hyperparathyroidism.
- Serum phosphate was inversely associated with adiposity, independent of PTH. FGF23 and body weight were correlated, suggesting that FGF23 may mediate the relationship between phosphate and adiposity.
- TZDs were associated with modest declines in BMD with no reversal after discontinuation. Avoidance of TZDs in those at high fracture risk may be prudent.
- Estimates of fracture risk were higher, on average, with Garvan than FRAX. However, using a 3% ten-year hip fracture risk as a treatment threshold, the calculators were in agreement in 75% of cases. It is reassuring that the calculators often agree, but important to recognize that each incorporates different risk factors.
- Supplementation with calcium as citrate resulted in attenuation of normal diurnal reductions in systolic blood pressure compared to placebo. Calcium supplements may work via this mechanism to increase cardiovascular risk.
- Compared to placebo, a single dose of oral dexamethasone did not reduce the likelihood or severity of APR following zoledronic acid infusion. A higher dose or longer dosing interval may be required.